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Abstract 
Background: Malaria cases were estimated to 207 million in 2013. One of the problems of malaria control is the 
emergence and spread of Plasmodium falciparum strains that become resistant to almost all drugs available. Monitor‑
ing drug resistance is essential for early detection and subsequent prevention of the spread of drug resistance by 
timely changes of treatment policy. This review was performed to gather all data available on P. falciparum molecular 
resistance in DR Congo, as baseline for future assessments.
Methods: The search for this review was undertaken using the electronic databases PubMed and Google Scholar 
using the terms “malaria”, “Congo”, “resistance”, “molecular”, “antimalarial”, “efficacy”. Articles were classified based on year 
of collecting, year of publication, sample size and characteristics, molecular markers analysed and polymorphisms 
detected.
Results: Thirteen articles were included and five genes have been analysed in these studies: pfcrt, pfdhps, pfdhfr, 
pfmdr1 and K13‑propeller. The majority of studies included were not representative of the whole country.
Conclusion: This systematic review demonstrates the lack of molecular resistance studies in DRC. Only 13 studies 
were identified in almost 15 years. The MOH must implement a national surveillance system for monitoring malaria 
drug resistance and this surveillance should be conducted frequently and country‑representative.
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Background
Malaria cases were estimated to 207 million in 2013, 
among with 584,000 deaths, 90 % found in Africa, Demo-
cratic Republic of Congo (DRC) and Nigeria together 
accounting for 40  % of the estimated global total [1]. 
The absence to date of an effective vaccine leaves us only 
chemotherapy to fight against Plasmodium falciparum 
infection, the most virulent Plasmodium species that 
infects humans. One of the problems of malaria control 
is the emergence and spread of P. falciparum strains that 
become resistant to almost all drugs available.
Chloroquine (CQ) was one of the most used molecules 
in the fight against malaria because of its cost-effective-
ness, but just some years after being placed on the mar-
ket, the first cases of chloroquine resistance emerged in 
Southeast Asia, then in Latin America before spreading 
to all endemic areas [2]. Later, this phenomenon was 
repeated for the other available drugs (proguanil, sul-
fadoxine–pyrimethamine, halofantrine, mefloquine). 
To prevent, or at least delay the onset of new resistant 
strains, WHO recommended in 2001 the use of drugs 
association and that one of the drugs be an artemisinin 
derivative [3]. At that time, no artemisinin resistance 
had been identified yet and many hopes were placed 
onto artemisinins. Unfortunately, in 2008 Noedl et  al. 
reported evidence of artemisinin resistance in Western 
Cambodia [4]. To date, artemisinin resistance has spread 
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to Thailand, Myanmar, Laos and Vietnam [5–7]. In 2014, 
Ariey et al. identified a molecular marker for artemisinin 
resistance [8].
Monitoring drug resistance is essential for early detec-
tion and subsequent prevention of the spread of drug 
resistance by timely changes of treatment policy. There 
are three possibilities to study drug resistance: in  vitro 
tests, in  vivo tests and study of molecular markers [9]. 
In vivo tests are the gold standard, as involving the 
three factors (human host, parasite and anti-malarial 
molecule), but they are difficult to implement and very 
expensive due to the heavy organizational machinery that 
must be in place (drugs, monitoring of patients for 24 or 
48 days, repeated biological tests, an experienced staff).
In vitro tests allow studying the inhibition of parasite 
growth in culture subjected to different concentrations of 
an anti-malarial. Their results do not reflect a real situ-
ation where parasites can survive in vivo in presence of 
an optimal serum concentration of the drug, as they do 
not consider host immunity or drug pharmacokinetics. 
These tests are also financially heavy and require live par-
asites, qualified persons for its implementation and labo-
ratory facilities for in  vitro culture. Finally, the study of 
molecular markers is a good alternative although the fac-
tors related to the host and the drugs are not taken into 
account. They can explore a wide range of markers (pre-
viously identified as related to resistance) onto large sam-
ples and in punctual manner. So the analysis of molecular 
markers gives a snapshot of the situation at a given time 
[10]. In DRC, which is the second largest African coun-
try, CQ was widely used for years till its withdrawal in 
2002, first replaced by sulfadoxine–pyrimethamine (SP), 
then by artemisinin-based combination therapy (ACT) 
[11]. Due to its size, studying malaria resistance in DRC 
by in  vitro or in  vivo methods would be very expensive 
and time-consuming; analysing molecular markers would 
be a better alternative.
This systematic review was performed to gather all data 
available on P. falciparum molecular resistance in DRC, 
as baseline for future assessments.
Methods
The search for this review was conducted during Novem-
ber 2014 and was undertaken using the electronic data-
bases Pub Med and Google scholar. The following search 
terms “malaria”, “Congo”, “resistance”, “molecular”, “anti-
malarial”, “efficacy” were used. Additional results were 
obtained from the references in the articles identified 
through the search. Selection criteria were: (a) samples 
related to malaria infection in DRC; (b) study compris-
ing analysis of one or more malaria resistance molecular 
marker; (c) original articles, short reports but no review 
articles. Full-text articles were read to check for selection 
criteria. An overall of 34 articles has been identified 
among which 16 were non-molecular studies and 5 were 
review articles or duplicates (based on same samples). 
Thirteen articles were finally included. Articles were clas-
sified based on year of collecting, year of publication, 
sample size and characteristics, molecular markers ana-
lyzed and polymorphisms detected. Figure  1 shows the 
search strategy used.
Results
The overall of the articles included in this review were of 
samples collected from 1999 to 2014 [12–24]. Some of 
them concerned non-Congolese people but supposed to 
have been infected in DRC. Five genes have been analysed 
in these studies: the Plasmodium falciparum chloroquine 
resistance transporter gene (pfcrt), the dihydropteroate 
synthase gene (pfdhps), the dihydrofolate reductase gene 
(pfdhfr), the Plasmodium falciparum multidrug resist-
ance 1 gene (pfmdr1) and the K13-propeller gene (k13).
The most analysed gene was pfcrt, linked to CQ and 
amodiaquine (AMQ) resistance [25, 26], and it has been 
studied in seven articles (53.8  %). Pfdhps, known to be 
related to sulfadoxine resistance [27] and pfdhfr for 
which evidence of point mutations conferring resistance 
to pyrimethamine has been made [28], have been respec-
tively analysed in five (38.4 %) and four articles (30.7 %). 
Analysis concerning K13-propeller and the pfmdr1 genes 
have been found, respectively in two (15.3  %) and one 
(7.6 %) studies. Pfmdr1 is correlated to resistance to many 
drugs as mefloquine (MQ), lumefantrine (LMF), AMQ 
and may be to artemisinin [29–32] and k13 is correlated 
to artemisinin resistance [8]. Table 1 provides a summary 
of the studies included in the review.
Fig. 1 Search strategy. Twenty‑one studies have been excluded after 
application of selection criteria
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pfcrt gene
On the seven studies involving the K76T mutation, four 
have also explored the haplotypes defined by specific 
mutations at amino acid positions 72–76 (related to 
AMQ resistance). The main findings of these articles are 
given in Table 2.
pfdhfr and pfdhps genes
Both genes are generally analysed together as they are 
related to SP combination susceptibility. Only one study 
analysed the dhps gene alone. Most point mutations ana-
lysed were on positions 51, 59 and 108 on dhfr and on 
positions 437 and 540 on dhps. Prevalence of point muta-
tions found in these studies is presented in Table 3.
K13‑propeller gene
Recently linked to artemisinin resistance, this gene has 
been analysed twice in sample from DRC. The older sam-
ples are about 2007 and the recent one is of 2013–2014. 
None of mutations related to artemisinin resistance dis-
covered in South-East Asia were found in DRC to date. 
All mutations found are shown in Table 4.
pfmdr1 gene
Only one study analysed this gene in Kinshasa. Five point 
mutations were explored on codons positions 86, 184, 
1034, 1042 and 1046. The N86Y mutation was present in 
66.7 % of samples studied [20].
Discussion
During almost 15  years, only 13 molecular stud-
ies were conducted based on samples from the DRC. 
These studies were of samples from 3 to 458 individuals 
(mean =  142) and that usually were focalized to one or 
two geographical sites. However, three studies [18, 19, 
21] were based on samples collected in the whole coun-
try as part of the Demographic and Health Survey (DHS), 
funded mostly by the international community [33]. 
Considering the size of the DRC (second largest African 
country with 2,345,000  km2) and the different patterns 
of malaria from one corner to another, results of most of 
these studies are not generalizable to the nationwide, but 
must be considered in their local context.
Sometimes for the same molecular markers in the 
same study, differences are significant in two different 
Table 1 Summary of the studies included in the review
a Considering only samples from DRC, not the total sample size of the study
Authors Year of collecting Year of publication Sample sizea Age Molecular markers
1. Andriantsoanirina et al. 1999, 2002, 2005 2010 3 – pfcrt
2. Severini et al. 2000 2005 32 – pfcrt
3. Wilson et al. 2002 2005 56 6–58 months pfcrt
4. Alker et al. 2002 2008 249 6–59 months pfdhfr, pfdhps
5. Cohuet et al. 2003–2004 2006 458 – pfdhfr, pfdhps
6. Swarthout et al. 2004 2006 168 6–59 months pfdhfr, pfdhps
7. Taylor et al. 2007 2013 179 >15 years dhps
8. Antonia et al. 2007 2014 180 >15 years pfcrt
9. Taylor et al. 2007 2014 151 >15 years K13
10. Mobula et al. 2008 2009 142 1–10 years pfcrt, pfmdr1, pfdhfr, pfdhps
11. Juliao et al. 2010 2013 12 19–55 years pfcrt
12. Mvumbi et al. 2010 2013 145 6–59 months pfcrt
13. Kamau et al. 2013–2014 2014 82 >6 years K13
Table 2 Main findings of studies that analysed the pfcrt gene
Authors Year of collecting Haplotypes found Mutant 76T
1. Andriantsoanirina et al. 1999, 2002, 2005 _ 3/3 100 %
2. Severini et al. 2000 CVIET, CVMNT, SVIET 27/27 100 %
3. Wilson et al. 2002 _ 52/56 93 %
4. Antonia et al. 2007 CVMNK, CVIET, CVMNT, CVMDK 92/166 55.4 %
5. Mobula et al. 2008 _ 88/105 83.8 %
6. Juliao et al. 2010 CVMNK, CVIET 1/12 8 %
7. Mvumbi et al. 2010 CVMNK, CVIET 148/198 73.2 %
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sites. The study of Cohuet et al. [16] illustrates well this 
fact: the prevalence of dhps double mutants (resist-
ance to sulfadoxine) was estimated at less than 1 % in a 
site (Basankusu) whereas it was close to 20 % in another 
(Kisangani). This would like to suggest that the molecule 
remains active in one place while it should be replaced by 
another. As WHO recommends withdrawal of a drug if 
the prevalence of resistant is above 10 %, this suggests in 
that case that the drug should be replaced in one place 
while it should be maintained in another. This underlines 
the fact that making national decision about treatment 
policy could not be based only on “localized” studies. The 
Ministry of Health should initiate, regularly, anti-malarial 
drugs efficacy monitoring studies but with a representa-
tive sampling. This scarcity of representative studies 
across the country is a real handicap. Treatment policies 
are applied in light of the available study (and thus the 
geographical location concerned). Thus, when changing 
the SP to ACT in the DRC, one of the studies available to 
support the selection of the combination AS + AQ com-
pared with AS + SP were localized to one site, Shabunda 
(East of the DRC) [17]. Maybe if another study was con-
ducted simultaneously in the West of the country, the 
data would have been different. The main hurdle is gener-
ally the high cost of surveillance studies, in particular for 
molecular studies that require equipment and reagents 
often unavailable locally. Thus, none of molecular analy-
sis performed for these 13 studies have been performed 
in a Congolese laboratory. All of the molecular analysis 
was carried out in Europe or in USA. Another implica-
tion of this high cost is that making these studies in a 
repetitive manner is very difficult. Yet the WHO experts 
recommend that the surveillance of the resistance must 
be carried out every 2 years in endemic countries [34].
The various data existing on the pfcrt gene confirm the 
decline of CQ resistant strains after its withdrawal. The 
latest available figures (which only concern Kinshasa) 
revealed a prevalence of 73.2  % [23], whereas previous 
studies before chloroquine replacement in 2002 were giv-
ing values beyond 90 % [12–14]. Unfortunately, as men-
tioned above, it is difficult to correctly compare these 
studies because of the differences in the applied method-
ology (essentially the sampling and the study location). It 
is important to notice that none of the studies concerning 
the pfcrt gene have detected the presence of the SVMNT 
haplotype (linked to AMQ resistance) in the DRC. As 
this haplotype was recently found in Angola [35] and 
Tanzania [36], two countries bordering the DRC, it would 
be prudent that a continuous and regular monitoring of 
the occurrence of this haplotype be conducted.
The SP was quickly removed for malaria first-line-treat-
ment in malaria endemic areas when many reports showed 
strong resistance rates. Studies conducted in the DRC 
have also confirmed it, but with important inter-sites and 
inter-studies variations [15–18]. It is not easy to say that 
SP resistance is declining or increasing because there were 
not two repetitive studies conducted in the same place, 
with the same methodology and at different time. Besides, 
it appears that SP resistance is more pronounced in the 
East than the West of the DRC. SP is nevertheless still used 
for intermittent preventive treatment in pregnant women 
(IPTp) and none of these studies assessed the impact of the 
use of this molecule in high resistance area.
At the time of the use of ACT, it is very important to 
monitor the emergence of artemisinin resistant strains 
in Africa. Indeed, this is the first time that a resistance 
molecular marker is identified before the resistant strains 
spreads to all malaria endemic regions. Actually, two 
studies were related to DRC samples on the k13-pro-
peller gene [21, 24]. None of polymorphisms identified 
in Southeast Asia have been found in the DRC but new 
mutations on k13 have been discovered in Africa. Further 
studies should be conducted to assess the impact of these 
new mutations on susceptibility to artemisinin.
Conclusion
Only 13 studies were identified in this review and the 
majority of them were not representative of the whole 
country. So their results are not generalizable. DRC is a 
very large country and malaria responses to drugs are very 
different from one place to another. Ministry of Health 
must implement a national surveillance system for moni-
toring malaria drug resistance and this surveillance should 
be conducted frequently, in many sentinel sites and this 
especially to react as fast as the occurrence of artemisinin-
resistant or AMQ-resistant strains in a part of the DRC.
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